Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) told investors it has completed the dosing phase of its canine gene therapy trial.
All enrolled dogs received full administration of the investigational SIRT6-based therapy, Genflow said in a statement.
The company reported no serious, moderate or minor adverse events during dosing. The trial is blinded, meaning efficacy outcomes cannot yet be assessed.
"These milestones represent an important step forward for our longevity program," said CEO Dr Eric Leire. "The absence of any adverse events is highly encouraging and reinforces the strong safety profile of our approach.
"We look forward to sharing initial efficacy data in the coming months as the study progresses."
The trial is testing whether the SIRT6 gene can improve DNA repair and metabolic regulation, two processes that weaken with age.
Results so far of an excellent safety and tolerability profile bolster confidence in the therapy’s potential.
Genflow is the only publicly listed longevity company in Europe and believes success in animals could open the door to a new segment of the multibillion-dollar animal health market.